THE 'ENHANCER' SNP DOES NOT EXPLAIN VARIABILITY OF CYP2D6 ACTIVITY IN VIVO.

被引：0
|
作者：
Boone, E. C. [1 ]
Staggs, V. T. [1 ]
Pearce, R. E. [1 ]
Lata, R. F. [1 ]
Gaedigk, R. [1 ]
Jaime, L. K. Montane [2 ]
Cherner, M. [3 ]
Berard, A. [4 ]
Fridley, B. L. [5 ]
Dinh, J. C. [1 ]
Miller, N. A. [1 ]
Leeder, J. [1 ]
Gaedigk, A. [1 ]
机构：
[1] Childrens Mercy Kansas City, Kansas City, MO USA
[2] Int Inst Hlth Care Profess, Boca Raton, FL USA
[3] Univ Calif San Diego, San Diego, CA 92103 USA
[4] Univ Montreal, Montreal, PQ, Canada
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-055
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [41] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
    Livezey, Mara R.
    Briggs, Erran D.
    Bolles, Amanda K.
    Nagy, Leslie D.
    Fujiwara, Rina
    Furge, Laura Lowe
    XENOBIOTICA, 2014, 44 (04) : 309 - 319
  • [42] Assessment of CYP2D6 activity in depressed patients
    Szewczuk-Bogusawska, M
    Orzechowska-Juzwenko, K
    Milejski, P
    Beszlej, JA
    Grzesiak, M
    Kiejna, A
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S219 - S219
  • [43] Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR
    Hersberger, M
    Marti-Jaun, J
    Rentsch, K
    Hänseler, E
    CLINICAL CHEMISTRY, 2000, 46 (08) : 1072 - 1077
  • [44] CYP2D6 activity in methadone maintenance patients
    Shiran, MR
    Rostami-Hodjegan, A
    Lennard, MS
    Iqbal, MZ
    Lagundoye, O
    Pratt, P
    Seiveright, N
    Tucker, GT
    JOURNAL OF PSYCHOPHARMACOLOGY, 2002, 16 (03) : A54 - A54
  • [45] The use of Yohimbine for phenotyping of CYP2D6 activity
    Vay, M.
    Rose, P.
    Meyer, M.
    Mikus, G.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 : S24 - S24
  • [46] Catalytic in vivo function of CYP2D6 in relation to the genotype
    Griese, EU
    Gaedigk, A
    Morike
    Mikus, G
    Zanger, U
    Eichelbaum, M
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 355 (04) : 458 - 458
  • [47] LONG-RANGE LINKAGE ANALYSIS TO ESTABLISH CYP2D6 'ENHANCER' SINGLE NUCLEOTIDE POLYMORPHISM (SNP) HAPLOTYPE.
    Gaedigk, A.
    Boone, E.
    Gaedigk, R.
    Wang, W.
    Miller, N.
    Leeder, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S86 - S86
  • [48] More data for the CYP2D6 hypothesis?:: The in vivo inhibition of CYP2D6 isoenzyme and extrapyramidal symptoms induced by antidepressants in the elderly
    García-Parajuá, P
    de Ugarte, L
    Baca, E
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (01) : 111 - 112
  • [49] Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity
    Dalton, Rachel
    Lee, Seung-been
    Claw, Katrina G.
    Prasad, Bhagwat
    Phillips, Brian R.
    Shen, Danny D.
    Wong, Lai Hong
    Fade, Mitch
    McDonald, Matthew G.
    Dunham, Maitreya J.
    Fowler, Douglas M.
    Rettie, Allan E.
    Schuetz, Erin
    Thornton, Timothy A.
    Nickerson, Deborah A.
    Gaedigk, Andrea
    Thummel, Kenneth E.
    Woodahl, Erica L.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (01): : 147 - 156
  • [50] Untangling SNP Variations within CYP2D6 Gene in Croatian Roma
    Markovic, Anita Stojanovic
    Petranovic, Matea Zajc
    Tomas, Zeljka
    Puljko, Borna
    Setinc, Maja
    Skaric-Juric, Tatjana
    Salihovic, Marijana Pericic
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (03):
12345